Chinese biotech company HitGen Inc (688222.SH) said on Saturday that it has extended the previous drug discovery research collaboration to identify small molecule leads against targets specified by Morphic Therapeutic.
Pursuant to the extended agreement, HitGen will use its DNA-encoded library (DEL) technology platform based on the design, synthesis and interrogation and selection to discover ligands for targets of interest to Morphic.
In conjunction with the collaboration, Morphic will pay an assignment fee to HitGen in exchange for exclusive development and commercialization rights to compounds that achieve the criteria of the collaboration.
Additionally, HitGen's industry-leading DNA-encoded library (DEL) technology platform includes over 400bn encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds.
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens
Nimbus Therapeutics partners with Lilly to develop oral obesity treatment
BioArctic and Eisai secure Chinese acceptance for subcutaneous Leqembi filing
Oculis secures FDA Breakthrough Therapy Designation for Privosegtor in optic neuritis
Nanjing Delova Biotech reports positive Phase 3 trial results for QP-6211 for postoperative pain
MetaVia reports positive results from Phase 1 clinical trial in obesity
RedHill advances RHB-102 across GI indications
Halozyme licenses ENHANZE to Skye Bioscience for nimacimab obesity programme
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
GSK secures China approval for Nucala in COPD
Insilico Medicine signs multi-year research and development collaboration with Servier
WuXi Biologics achieves ISO 20400 Sustainable Procurement certification
ChemPartner updates its visual identity and digital experience